2-Dimethylaminoethyl Chloride HCl: Tianming Large-Scale Supply

Sourcing 2-Dimethylaminoethyl chloride hydrochloride for pharmaceutical synthesis is rarely as simple as placing an order. Buyers must weigh purity consistency, documentation depth, and whether a supplier can move from gram-level trial quantities to commercial tonnage without disruption. Shandong Tianming Pharmaceutical Group, operating under the brand Tianming Pharmaceutical, addresses this sourcing challenge through an integrated R&D-production model built specifically for pharmaceutical raw material and intermediate supply.

Understanding the Sourcing Challenge for Specialty Intermediates

Procurement teams searching for 2-Dimethylaminoethyl chloride hydrochloride and similar building blocks commonly encounter a recurring set of obstacles. According to the industry pain point insight documented by Tianming Pharmaceutical, these include extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality that causes production interruptions, and fragmented sourcing across multiple suppliers that raises overall procurement costs. Additional friction arises when process parameters for niche intermediate categories are difficult to match, or when upstream intermediate introductions lag behind new drug iteration cycles. Any company evaluating suppliers for this compound should treat these five pain points as a practical checklist rather than abstract concerns, since each one translates directly into cost, delay, or regulatory risk downstream.

Why Production Scale and Quality Systems Matter

Large-scale production capability is not simply a matter of reactor count. It requires a quality architecture that keeps every batch within specification regardless of volume. Tianming Pharmaceutical operates three coordinated production bases with more than 160 reactor vessels in total, supporting an annual production capacity in the hundreds of tons. This infrastructure is paired with a Large-compliant quality assurance system and ISO9001 Quality Management System Certification, which has been awarded to both Shandong Sihuan Pharmaceutical Co., Ltd. (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. (2024), the group’s two production entities. Full batch traceability is maintained across raw material receipt, reaction parameters, purification processes, and testing data, with all records archived for complete chain-of-custody traceability. For buyers of 2-Dimethylaminoethyl chloride hydrochloride who plan to scale from pilot batches to commercial manufacturing, this combination of reactor capacity and documented quality control is the structural foundation that determines whether a supplier relationship can grow without renegotiating quality terms at every volume tier.

An Integrated Group Structure Behind the Supply

Shandong Tianming Pharmaceutical Group was formally established in 2020, building on its predecessor Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010. The group is headquartered in Jinan, Shandong Province, and today coordinates two R&D centers, three domestic production bases, and two overseas business entities. The production footprint includes Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Jining Tianming Pharmaceutical Co., Ltd. in Jining, and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi, Guangxi, while R&D activity is anchored by centers in Jinan and Nanjing with a combined laboratory area exceeding 6,000 square meters and an R&D team of more than 100 personnel. The group’s business coverage spans domestic China—East China, North China, and South China pharmaceutical industry clusters—alongside international markets across more than 30 countries and regions in South Asia, Southeast Asia, the Middle East, Central and South America, and Africa, supported by overseas business entities in India and Bangladesh. This structure allows Tianming Pharmaceutical to serve both domestic buyers and international pharmaceutical supply chains from a single coordinated operation rather than through disconnected regional units.

Documentation and Regulatory-Grade Quality Control

For intermediates such as 2-Dimethylaminoethyl chloride hydrochloride, documentation quality often matters as much as the physical product. Tianming Pharmaceutical maintains complete technical documentation—including COA, MOA methodology, impurity profile studies, and stability data—designed to support DMF and CEP global regulatory filings. This documentation is generated and managed through a CRM, ERP, and BPM digital management system that coordinates order management, inventory, production scheduling, and customer service, enabling rapid domestic order confirmation alongside full international logistics chain services. Buyers preparing regulatory submissions or supplier qualification files can draw on this documentation set directly rather than assembling it from multiple fragmented sources, which directly addresses the fragmented-sourcing pain point noted earlier.

Scalable Supply From Gram to Ton

Tianming Pharmaceutical’s stated delivery capability reflects the practical needs of pharmaceutical buyers at different project stages. In-stock orders are delivered within 7 to 15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability, with expedited production scheduling available for urgent projects. Service is structured around a 1-on-1 account manager plus technical engineer dual support model: routine technical issues are addressed with reference solutions within 2 hours, while complex technical issues are resolved with a written report within 24 hours. Periodic follow-up visits and on-site technical support are available for bulk and framework customers. For an intermediate like 2-Dimethylaminoethyl chloride hydrochloride, this means a buyer can request small-batch samples for qualification work and later transition to larger production runs within the same service framework, rather than switching suppliers between development and commercial phases.

A Diversified Portfolio Supporting Multiple Industries

Within its product matrix, Tianming Pharmaceutical lists N,N-Dimethylaminoethane hydrochloride (CAS: 4584467) among its “Other Products” category, a listing that corresponds to the compound commonly referenced as 2-Dimethylaminoethyl chloride hydrochloride. This entry sits alongside a broader catalog spanning cardiovascular, anti-infective, anti-diabetic, anti-tumor, nervous system, and cosmetic and food ingredient intermediates, totaling 98 listed products and services across the group. This breadth reflects the company’s positioning as an R&D-driven pharmaceutical raw material and intermediate enterprise offering API, intermediates, and CMO/CDMO custom development and production solutions, rather than a single-molecule specialist.

Honors and Recognitions Reinforcing Operational Reliability

Tianming Pharmaceutical’s production entities have received a series of qualifications that reflect ongoing operational and innovation standards. Shandong Sihuan Pharmaceutical Co., Ltd. and Shandong Tianming Pharmaceutical Technology Co., Ltd. both hold National High-Tech Enterprise status, alongside Guangxi Tianming Pharmaceutical Co., Ltd. Provincial recognitions include Shandong Province Gazelle Enterprise, Guangxi Gazelle Enterprise, and multiple Specialized and Innovative SME designations across the group’s entities. The company is also recognized as a National Technology-based SME and hosts the “New Pharmaceutical Intermediates” Engineering Research Center, supported by a Shandong Province Postdoctoral Innovation Practice Base.

For procurement teams evaluating global suppliers of 2-Dimethylaminoethyl chloride hydrochloride, the combination of documented quality systems, multi-base production capacity, full regulatory documentation, and a service model built around technical responsiveness positions Shandong Tianming Pharmaceutical Group as a structured option for both development-stage sampling and large-scale commercial supply.

Home

Tianming Pharmaceutical Group